What is TALVEY and how does it work?

TALVEY (talquetamab) is a bispecific antibody targeting CD3 on T-cells and GPRC5D on myeloma cells, helping the immune system attack cancer.

What is IMAAVY and what disease does it treat?

IMAAVY (nipocalimab) is a monoclonal antibody that treats warm autoimmune hemolytic anemia by inhibiting FcRn, reducing red blood cell destruction.

What are TECNIS PureSee lenses?

TECNIS PureSee is an extended depth of focus intraocular lens that provides clear vision at multiple distances after cataract surgery, reducing the need for glasses.

Johnson & Johnson Strengthens Portfolio with Oncology, Rare Disease, and MedTech Advances

Johnson & Johnson announced progress in three key areas: bispecific oncology therapies, rare autoimmune diseases, and premium MedTech optics, reinforcing its position in high-value healthcare.

In mid-June 2026, Johnson & Johnson (JNJ) reported strong clinical data for TALVEY combinations in relapsed/refractory multiple myeloma, positive Phase 2/3 ENERGY results for IMAAVY in warm autoimmune hemolytic anemia, and broader U.S. availability of its TECNIS PureSee extended depth of focus intraocular lens.

The Products

TALVEY (talquetamab)

TALVEY is a bispecific antibody targeting CD3 and GPRC5D, showing promising results in patients who have failed prior therapies for multiple myeloma. New data support its use in combination regimens.

IMAAVY (nipocalimab)

IMAAVY is an anti-FcRn monoclonal antibody that demonstrated improvements in hemoglobin levels and reduced transfusion needs in patients with warm autoimmune hemolytic anemia.

TECNIS PureSee

An extended depth of focus intraocular lens providing clear vision at multiple distances, reducing dependence on glasses after cataract surgery.

Pricing and Availability

Pricing details have not been disclosed. TECNIS PureSee is now more widely available in the U.S. following FDA approval.

Competition

TALVEY faces competition from other bispecifics like teclistamab (Janssen). IMAAVY competes with efgartigimod (argenx). In the IOL market, TECNIS PureSee competes with lenses from Alcon and Bausch + Lomb.

Potential Impact on the Company

These advances strengthen Johnson & Johnson's presence in oncology, rare diseases, and MedTech, potentially diversifying its revenue streams and reducing reliance on traditional products.